Jefferies on Mineralys Therapeutics, Inc. (MLYS): 'Historical Trends Suggests M&A Is Still Statistically Possible Before PDUFA'
Tweet Send to a Friend
Jefferies analyst Dennis Ding reiterated a Hold rating and $30.00 price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
